Browsing Tag
SIMPONI
2 posts
FDA accepts Alvotech and Teva’s BLA for AVT05, advancing first golimumab biosimilar in the U.S.
FDA accepts Alvotech and Teva’s BLA for AVT05, a proposed golimumab biosimilar — find out how this milestone strengthens U.S. biosimilar competition.
Johnson & Johnson (NYSE: JNJ) gains FDA approval to expand SIMPONI into pediatric ulcerative colitis
FDA approves SIMPONI (golimumab) for children ≥15 kg with ulcerative colitis, expanding Johnson & Johnson’s immunology portfolio. Learn what it means for patients.